Target intelligence / Profile preview

novel transcript, antisense to AP1S2 (ENSG00000307891)

Target
ENSG00000307891
Molecular classification
Other (long non-coding RNA or lncRNA)
01

Overview

This entity represents a long non-coding RNA transcript (lncRNA) annotated antisense to the AP1S2 gene. Its sequence overlaps or is opposite to the AP1S2 coding region, but it is not known to encode a functional protein or have a characterized role in molecular biology or disease. Antisense lncRNAs can sometimes act as regulators of sense gene transcription or post-transcriptional events, but for ENSG00000307891, there is no experimental evidence or disease linkage described in current databases. The AP1S2 gene itself encodes the sigma 2 subunit of the clathrin-associated adaptor protein complex 1, which is involved in protein sorting in the Golgi- and trans-Golgi network and has disease relevance in certain inherited mental retardation syndromes. If searching for a classical drug target, this transcript is likely not relevant. The AP1S2 gene/protein would be the relevant entity for traditional target information.

Other names
novel transcript, antisense to AP1S2ENSG00000307891GC0XP015853
02

Mechanism of action

None characterized.

03

Biological functions

Unknown. Most antisense lncRNAs may regulate expression of their sense counterpart (AP1S2) via transcriptional interference, RNA duplex formation, or chromatin modification, but no specific biological function characterized for this transcript in humans.
04

Disease associations

None confirmed. No direct association with disease is described for this transcript; AP1S2 itself is implicated in neurodevelopmental disorders (mental retardation syndromes), but the antisense lncRNA is not characterized in disease.
05

Safety considerations

None reported or anticipated, as it is not a clinical or pharmacological entity.
06

Interacting drugs

None known
07

Biomarkers

None identified

Beyond the preview

Go deeper on novel transcript, antisense to AP1S2 (ENSG00000307891).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on novel transcript, antisense to AP1S2 (ENSG00000307891).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call